Patients allocated to avosentan had a median body weight increase of 0.6 kg ( interquartile range , 0.0 to 2.0 kg ) and a median hemoglobin decrease of 1.4 g/dl ( interquartile range , -2.1 to -0.7 g/dl ) at the first postrandomization measurement .